Cancer immunotherapies with monoclonal antibodies (mAbs) against immune checkpoints (i.e., CTLA-4 and PD-1/PD-L1) have revolutionized antineoplastic treatments. Immune checkpoint inhibitors (ICIs) approved for cancer immunotherapy are mAbs anti-CTLA-4 (ipilimumab), anti-PD-1 (nivolumab, pembrolizumab, and cemiplimab), and anti-PD-L1 (atezolizumab, avelumab, and durvalumab). Treatment with ICIs can be associated with immune-related adverse events (irAEs), including an increased risk of developing myocarditis. These findings are compatible with the observation that, CTLA-4, PD-1, and PD-L1 pathways play a central role in the modulation of autoimmunity.

How can we manage the cardiac toxicity of immune checkpoint inhibitors? / Poto, Remo; Marone, Giancarlo; Pirozzi, Flora; Galdiero, Maria Rosaria; Cuomo, Alessandra; Formisano, Luigi; Bianco, Roberto; Della Corte, Carminia Maria; Morgillo, Floriana; Napolitano, Stefania; Troiani, Teresa; Tocchetti, Carlo G; Mercurio, Valentina; Varricchi, Gilda. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - (2021). [10.1080/14740338.2021.1906860]

How can we manage the cardiac toxicity of immune checkpoint inhibitors?

Poto, Remo;Marone, Giancarlo;Pirozzi, Flora;Galdiero, Maria Rosaria;Cuomo, Alessandra;Formisano, Luigi;Bianco, Roberto;Tocchetti, Carlo G
;
Mercurio, Valentina;Varricchi, Gilda
2021

Abstract

Cancer immunotherapies with monoclonal antibodies (mAbs) against immune checkpoints (i.e., CTLA-4 and PD-1/PD-L1) have revolutionized antineoplastic treatments. Immune checkpoint inhibitors (ICIs) approved for cancer immunotherapy are mAbs anti-CTLA-4 (ipilimumab), anti-PD-1 (nivolumab, pembrolizumab, and cemiplimab), and anti-PD-L1 (atezolizumab, avelumab, and durvalumab). Treatment with ICIs can be associated with immune-related adverse events (irAEs), including an increased risk of developing myocarditis. These findings are compatible with the observation that, CTLA-4, PD-1, and PD-L1 pathways play a central role in the modulation of autoimmunity.
2021
How can we manage the cardiac toxicity of immune checkpoint inhibitors? / Poto, Remo; Marone, Giancarlo; Pirozzi, Flora; Galdiero, Maria Rosaria; Cuomo, Alessandra; Formisano, Luigi; Bianco, Roberto; Della Corte, Carminia Maria; Morgillo, Floriana; Napolitano, Stefania; Troiani, Teresa; Tocchetti, Carlo G; Mercurio, Valentina; Varricchi, Gilda. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - (2021). [10.1080/14740338.2021.1906860]
File in questo prodotto:
File Dimensione Formato  
poto IEDS_A_1906860 (1).pdf

solo utenti autorizzati

Licenza: Accesso privato/ristretto
Dimensione 2.12 MB
Formato Adobe PDF
2.12 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/848968
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact